{"id":"W4256446122","doi":"10.1158/2159-8290.cd-nb2019-113","title":"Collaborative Review, Concurrent Approval","year":2019,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Pembrolizumab; Lenvatinib; Drug approval; Medicine; Drug; Cancer; Oncology; Pharmacology; Internal medicine; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06720395,0.001210444,0.002092712,0.006021087,0.00207977,0.009805821,0.003532815,0.009463334,0.03343621],"category_scores_gemma":[0.1762561,0.0008812383,0.002871681,0.004196788,0.003615141,0.007211342,0.00598796,0.01034834,0.01196416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007501842,"about_ca_system_score_gemma":0.03408711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004049941,"about_ca_topic_score_gemma":0.006080665,"domain_scores_codex":[0.9064074,0.04122723,0.009192953,0.006846509,0.03397026,0.002355623],"domain_scores_gemma":[0.814379,0.05489483,0.01953422,0.01965498,0.08236928,0.009167657],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004910651,0.0001617558,0.0002822387,0.009281501,0.0005615011,0.000243118,0.000144294,0.0003322386,0.0005577162,0.03391286,0.6977936,0.2562381],"study_design_scores_gemma":[0.0006152157,0.0001912271,0.0003445562,0.005084553,0.0002959727,0.0003732571,0.00004548144,0.0002555672,0.0002683959,0.007768267,0.9847302,0.00002740362],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"commentary","genre_scores_codex":[0.001497207,0.4782845,0.0138614,0.2054269,0.09874289,0.00540638,0.002438376,0.0006248183,0.1937176],"genre_scores_gemma":[0.07779312,0.4218129,0.03018802,0.2186464,0.1193655,0.00992835,0.003981687,0.0006571407,0.1176269],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.06720395,"threshold_uncertainty_score":0.3554127,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01697361601396653,"score_gpt":0.3264949462644223,"score_spread":0.3095213302504558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}